The (Oroeze) Benzydamine 0.15% w/v Oromucosal spray is available in the Teva 360 livery.
The new product is a version of Difflam (Benzydamine) from Meda Pharmaceuticals.
Teva commercial director Kim Innes said, "As the leading supplier of generic medicines and with the widest portfolio of our competitors, Teva continues with strong product launches and patent expiries. We’ve already launched eighteen new products this year including ten on day-one of patent expiry."
The (Oroeze) Benzydamine 0.15% w/v Oromucosal spray is indicated as an analgesic and anti-inflammatory treatment for the throat and mouth.
The product is especially indicated as an analgesic in traumatic conditions such as following tonsillectomy or the use of a naso-gastric tube and dental surgery.